Novartis’ CAR T therapy Kymriah nails main goal in follicular lymphoma

pharmafile | August 4, 2020 | News story | Manufacturing and Production, Research and Development CAR-T therapy, Cancer, Kymriah, Novartis, car t therapy 

Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL), revealing that the therapy met its primary its primary endpoint of complete response rate (CRR) in Phase 2 trials, according to an independent review committee.

The findings are significant for a treatment of this stature. Kymriah was the first CAR T therapy to secure approval from the FDA, and is currently authorised for use in the treatment of acute lymphoblastic leukaemia (ALL) and r/r adult diffuse large B-cell lymphoma (DLBCL) in patients up to 25 years of age.

The company said it continues to expand its manufacturing capacity for the therapy as it closes in on a third approved indication, with seven facilities across four continents contributing to the production of the drug worldwide.

“We are pleased that Kymriah is showing meaningful results and may provide a potentially definitive treatment option for patients with relapsed and refractory follicular lymphoma,” remarked Dr John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis. “These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments.”

Novartis confirmed that full results from the study would be revealed at a future medical event and that the data will be submitted to US and European regulators.

Matt Fellows

Related Content


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …


GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test

US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective …

ISA Pharmaceuticals highlights positive clinical data at ASCO

Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American …

Latest content